利伐沙班与低分子肝素预防肿瘤血栓有效性和安全性分析  

Comparative Analysis of the Efficacy and Safety of Rivaroxaban versus Low Molecular Weight Heparin for Thromboprophylaxis in Cancer-Associated Thrombosis

作　　者：朱小丽 ZHU Xiao-li(Department of Pharmacy,Red Cross Hospital of Yulin Cit,Yulin Guangxi,537000,China)

机构地区：[1]玉林市红十字会医院药学部,广西玉林537000

出　　处：《中华养生保健》2025年第8期47-51,共5页CHINESE HEALTH CARE

摘　　要：目的评估利伐沙班与低分子肝素(LMWH)用于肿瘤血栓预防的有效性和安全性,以期为临床使用抗凝药预防肿瘤血栓提供参考。方法回顾性分析玉林市红十字会医院2022年6月—2023年3月恶性肿瘤患者193例,分为利伐沙班组(n=98),LMWH组(n=95),比较分析两组患者用药后1个月内及6个月内血栓发生率、出血发生率、死亡率。结果两组用药后1个月内及随访6个月内血栓发生率、出血发生率、死亡率比较,差异均无统计学意义(P>0.05)。结论与低分子肝素相比,利伐沙班用于恶性肿瘤血栓预防的有效性与安全性相当,或可作为拒绝或无法耐受皮下注射的合理替代药物。Objective To assess the effi cacy and safety of rivaroxaban compared to low molecular weight heparin(LMWH)for thromboprophylaxis in cancer patients,aiming to provide clinical guidance on anticoagulant therapy for preventing cancer-related thrombosis.Methods A retrospective analysis was conducted involving 193 patients with malignant tumors from Yulin Red Cross Hospital between June 2022 and March 2023.Patients were divided into the rivaroxaban group(n=98)and the LMWH group(n=95).The incidence of thrombosis,bleeding,and mortality within one month and six months post-treatment were compared between the two groups.Results There were no statistically signifi cant diff erences in the rates of thrombosis,bleeding,or mortality between the two groups at one month and during the six-month follow-up(P>0.05).Conclusion Rivaroxaban demonstrates comparable effi cacy and safety to LMWH for thromboprophylaxis in malignant tumors,or can be used as a reasonable alternative to refusal or inability to tolerate subcutaneous injection.

关 键 词：利伐沙班 低分子肝素 预防 肿瘤血栓 

分 类 号：R273[医药卫生—中西医结合]